Xintela ABFRA:1XT +6.25%8 Market Cap is €15.83 Mil as of Jul. 05, 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 1,426 Biotechnology companies, Xintela AB ranks worse than 77.91% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xintela AB's share price for the quarter that ended in Mar. 2026 was €0.01. Xintela AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 861.27 Mil. Therefore, Xintela AB's market cap for the quarter that ended in Mar. 2026 was €8.61 Mil.
Xintela AB's quarterly market cap
declined
from Sep. 2025 (€17.16 Mil) to Dec. 2025 (€11.89 Mil) and
declined
from Dec. 2025 (€11.89 Mil) to Mar. 2026 (€8.61 Mil).
Xintela AB's annual market cap
increased
from Dec. 2023 (€7.30 Mil) to Dec. 2024 (€9.77 Mil) and
increased
from Dec. 2024 (€9.77 Mil) to Dec. 2025 (€11.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xintela AB's Enterprise Value for Today is €15.54 Mil.
Xintela AB (FRA:1XT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Xintela AB Market Cap Related Terms
Xintela AB Market Cap Historical Data
* Premium members only.
The historical data trend for Xintela AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1XT vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Xintela AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Xintela AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Xintela AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB (FRA:1XT) has a Market Cap of €15.83 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #1111 out of 1426 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Xintela AB's Market Cap too high?
Xintela AB's current Market Cap is €15.83 Mil. Based on the distribution chart, Xintela AB ranks #1111 out of 1426 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #1111 out of 1426 companies for Market Cap. This places Xintela AB in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xintela AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xintela AB's current Market Cap is €15.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current Market Cap of €15.83 Mil. The current Market Cap is €15.83 Mil. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current Market Cap is €15.83 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for FRA:1XT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1XT has been successfully added to your 
